Novartis on Wednesday announced it has voluntarily put on hold any future price hikes planned for 2018, according to Endpoint News.
“We have voluntarily pulled back on any further price increases this year,” Novartis CEO Vas Narasimhan told reporters.
The move comes as the pharmaceutical giant’s ties to President Donald Trump’s administration are under fire following news former CEO, Joe Jimenez, had signed off on a $1.2 million contracting contract with Michael Cohen, Trump’s personal attorney.
